As of today (2024-04-18), Denali Therapeutics's share price is $16.60.
Denali Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.58. Hence, Denali Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Denali Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 9 years, Denali Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 45.14. The lowest was 16.35. And the median was 21.36.
Denali Therapeutics's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $-0.71.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.58.
During the past 9 years, Denali Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 47.90% per year. The lowest was -7.10% per year. And the median was 20.40% per year.
Denali Therapeutics Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Denali Therapeutics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Denali Therapeutics Annual Data
|
|
Trend |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
|
|
|
|
- |
22.69 |
- |
- |
- |
|
Denali Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison
For the Biotechnology subindustry, Denali Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics Price-to-Operating-Cash-Flow Distribution
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's Price-to-Operating-Cash-Flow falls into.
Denali Therapeutics Price-to-Operating-Cash-Flow Calculation
Denali Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 16.60 | / | -2.583 |
| = | |
Denali Therapeutics's Share Price of today is $16.60.
Denali Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.58.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Denali Therapeutics (Denali Therapeutics) Business Description
Traded in Other Exchanges
Address
161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Executives
| Vicki L Sato |
director |
940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
| Carole Ho |
officer: Chief Medical Officer |
C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Ryan J. Watts |
director, officer: President and CEO |
C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Steve E. Krognes |
officer: CFO and Treasurer |
863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
| Alexander O. Schuth |
officer: COO and Secretary |
C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Marc Tessier-lavigne |
director |
1 DNA WAY, SOUTH SAN FRANCISCO CA 94080 |
| Erik Harris |
director |
60 LEVERONI COURT, NOVATO CA 94949 |
| Douglas K Bratton |
10 percent owner |
201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102 |
| Nancy Thornberry |
director |
SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036 |
| David P Schenkein |
director |
C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Biogen Inc. |
10 percent owner |
225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Biogen Ma Inc. |
10 percent owner |
225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Arch Venture Partners Viii, L.p. |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
| Arch Venture Partners Viii, Llc |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
| Arch Venture Fund Viii, L.p. |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Denali Therapeutics (Denali Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DNLI has been successfully added to your